Prostate cancer immunotherapy

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019;144(8):1941–1953.
   PubMed Web of Science ®Google Scholar
• Moussa M, Papatsoris A, Sryropoulou D, et al. A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. Expert Opin Pharmacother. 2021 Sep;22(13):1685–1728.
   PubMed Web of Science ®Google Scholar
• Scher HI, Solo K, Valant J, et al. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: estimates Using a Dynamic Progression Model. PloS One. 2015;10(10):e0139440.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213–223.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Koga N, Moriya F, et al. Immunotherapy in prostate cancer: challenges and opportunities. Immunotherapy. 2016;8(1):69–77.
   PubMed Web of Science ®Google Scholar
• (NCCN) NCCN. Clinical Practive Guidelines in Oncology (NCCN Guidelines). Prostate Cancer. Version 2. 2021. **Important practical Guidelines for PCa treatment from the oncologist perspective
   Google Scholar
• Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000 May 1;60(9):2444–2448.
   PubMed Web of Science ®Google Scholar
• Reimers MA, Slane KE, Pachynski RK. Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: past and Future Strategies for Optimization. Curr Urol Rep. 2019 Sep 3;20(10):64.
   PubMed Web of Science ®Google Scholar
• Hamid AA, Choudhury AD. Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer. Curr Opin Urol. 2020 Jan;30(1):30–35.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011 Dec 20;29(36):4828–4836.
   PubMed Web of Science ®Google Scholar
• Olson BM, McNeel DG. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother. 2011 Jun;60(6):781–792.
   PubMed Web of Science ®Google Scholar
• Alhalabi O, Bilen MA. Current landscape of immunotherapy in genitourinary malignancies. Adv Exp Med Biol. 2020;1244:107–147.
   PubMed Web of Science ®Google Scholar
• Johnson LE, Frye TP, Chinnasamy N, et al. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother. 2007 Jun;56(6):885–895.
   PubMed Web of Science ®Google Scholar
• Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA. 2001 Dec 4;98(25):14565–14570.
   PubMed Web of Science ®Google Scholar
• Gannon PO, Poisson AO, Delvoye N, et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009 Aug 31;348(1–2):9–17.
   PubMed Web of Science ®Google Scholar
• Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol. 2009 Feb;27(2):129–139.
   PubMed Web of Science ®Google Scholar
• Cornford P, van Den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021 Feb;79(2):263–282.
   PubMed Web of Science ®Google Scholar
• NCT00005947. Vaccine therapy in treating patients with metastatic prostate cancer that has not responded to hormone therapy, 2004 March 5 cited 2021 Aug 14]. Available from 2021 Aug 14: https://www.clinicaltrials.gov/ct2/show/NCT00005947.
   Google Scholar
• Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089–3094.
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009 Aug 15;115(16):3670–3679.
   PubMed Web of Science ®Google Scholar
• Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2011 Jul 1;17(13):4558–4567.
   PubMed Web of Science ®Google Scholar
• NCT03686683. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (ProVent), 2018 September 27 cited Aug 2021 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT03686683.
   Google Scholar
• Schepisi G, Farolfi A, Conteduca V, et al. Immunotherapy for Prostate Cancer: where We Are Headed. Int J Mol Sci. 2017 Dec 5;18(12). doi:https://doi.org/10.3390/ijms18122627.
   Google Scholar
• Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, et al. Immunotherapy with dendritic cells for prostate cancer. Int J Cancer. 2007 Aug 1;121(3):467–473.
   PubMed Web of Science ®Google Scholar
• Kodumudi KN, Woan K, Gilvary DL, et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res off J Am Assoc Cancer Res. 2010 Sep 15;16(18):4583–4594.
   PubMed Web of Science ®Google Scholar
• Podrazil M, Horvath R, Becht E, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2015 Jul 20;6(20):18192–18205.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Borre M, Vogelzang NJ, et al. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019 May 1;37(13):1051–1061.
   PubMed Web of Science ®Google Scholar
• Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE); 2018 March 08 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT02111577.
   Google Scholar
• Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem. 2011 Aug;112(8):1969–1977.
   PubMed Web of Science ®Google Scholar
• Rojas-Martínez A, Manzanera AG, Sukin SW, et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther. 2013 Nov;20(11):642–649.
   PubMed Web of Science ®Google Scholar
• Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PrTK03); 2011 Sep 20 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT01436968?term=NCT01436968&draw=2&rank=1.
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517–2526.
   PubMed Web of Science ®Google Scholar
• van Den Eertwegh AJM, Versluis J, van Den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509–517.
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jun;15(7):700–712.
   PubMed Web of Science ®Google Scholar
• Beer TM, Kwon ED, Drake CG, et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol. 2017 Jan;35(1):40–47.
   PubMed Web of Science ®Google Scholar
• Sharma P, Pachynski RK, Narayan V, et al. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020 Oct 12;38(4):489–499.e483.
   PubMed Web of Science ®Google Scholar
• A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer; 2019 March 18 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT03879122?term=NCT03879122&draw=2&rank=1.
   Google Scholar
• Thakur A, Vaishampayan U, Lum LG. Immunotherapy and Immune Evasion in Prostate Cancer. Cancers (Basel). 2013;5(2):569–590.
   PubMedGoogle Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814–1823.
   PubMed Web of Science ®Google Scholar
• Viola D, Cappagli V, Elisei R. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol. 2013 Aug;9(8):1083–1092.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 Jul 5;379(1):54–63.
   PubMed Web of Science ®Google Scholar
• Smith M, De Bono J, Sternberg C, et al. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. J Clin Oncol. 2016 Sep 1;34(25):3005–3013.
   PubMed Web of Science ®Google Scholar
• Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02), 2020 June 24 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT04446117?term=NCT04446117&draw=2&rank=1.
   Google Scholar
• Gupta N, Al Ustwani O, Shen L, et al. Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. Onco Targets Ther. 2014;7:223–234.
   PubMed Web of Science ®Google Scholar
• Shen L, Sundstedt A, Ciesielski M, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res. 2015 Feb;3(2):136–148.
   PubMed Web of Science ®Google Scholar
• Sternberg C, Armstrong A, Pili R, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 Aug 1;34(22):2636–2643.
   PubMed Web of Science ®Google Scholar
• Isaacs JT, Antony L, Dalrymple SL, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013 Feb 15;73(4):1386–1399.
   PubMed Web of Science ®Google Scholar
• Park SR, Chen A. Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am. 2012 Jun;26(3):649–670.
   PubMed Web of Science ®Google Scholar
• Patel M, Nowsheen S, Maraboyina S, et al. The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. Cell Biosci. 2020;10:35.
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016;375(5):443–453.
   PubMed Web of Science ®Google Scholar
• Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012 Jul 12;487(7406):239–243.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005 Apr 14;434(7035):917–921.
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123–134.
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Omlin A, Hylands L, et al. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol. 2013 May;24(5):1416–1418.
   PubMed Web of Science ®Google Scholar
• Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015 Oct 29;373(18):1697–1708.
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al., Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 382(22): 2091–2102. 2020.
   PubMed Web of Science ®Google Scholar
• Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer, 2018 November 7 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT03732820.
   Google Scholar
• Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010), 2019 February 8 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT03834519.
   Google Scholar
• A Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC), 2020 December 31 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT04691804.
   Google Scholar
• NCT02975934. A Study of Rucaparib Versus Physician’s Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3), 2016 November 29 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT02975934.
   Google Scholar
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE), 2020 August 4 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT04497844.
   Google Scholar
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE), 2021 November 21 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT03748641.
   Google Scholar
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC, 2021 March 29 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT04821622.
   Google Scholar
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2), 2018 January 10 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT03395197.
   Google Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742.
   PubMed Web of Science ®Google Scholar
• Package Insert. KEYTRUDA(pembrolizumab). Whitehouse Station NMC, Inc.; 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s031lbl.pdf. cited 2021 May 11.
   Google Scholar
• Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016 Aug 16;7(33):52810–52817.
   PubMed Web of Science ®Google Scholar
• Abida W, Cheng ML, Armenia J, et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2019 Apr 1;5(4):471–478.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, N.Y.). 2017 Jul 28;357(6349):409–413.
   PubMed Web of Science ®Google Scholar
• Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018 Aug 1;29(8):1807–1813.
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991), 2019 December 9 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT04191096.
   Google Scholar
• Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641), 2019 February 8 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT03834493.
   Google Scholar
• Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921), 2019 Feb 8 [cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT03834506.
   Google Scholar
• A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250), 2017 January cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT03016312.
   Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563–567.
   PubMed Web of Science ®Google Scholar
• A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX), 2019 September 23 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT04100018.
   Google Scholar
• Mesters JR, Barinka C, Li W, et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006 Mar 22;25(6):1375–1384.
   PubMed Web of Science ®Google Scholar
• Von Eyben FE, Baumann GS, Baum RP. PSMA diagnostics and treatments of prostate cancer become mature. Clin Transl Imaging. 2018;6(2):145–148.
   PubMed Web of Science ®Google Scholar
• Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2021 Jul;80(1):82–94.
   PubMed Web of Science ®Google Scholar
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition), 2021 June 9 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT04720157?term=177Lu&draw=7.
   Google Scholar
• Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH), 2021 February 25 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT04647526.
   Google Scholar
• 177Lu-DOTA-rosopatamab With Best Standard of Care (SoC) for the Second Line of Treatment for Metastatic Castrate-resistant Prostate Cancer, Which Expresses PSMA (PROSTACT), 2021 May 6 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/study/NCT04876651.
   Google Scholar
• Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION), 2018 May 23 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT03511664.
   Google Scholar
• 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PSMAfore), 2021 June 15 cited 2021 Aug 14]. Available from 2021 Aug 14: https://clinicaltrials.gov/ct2/show/NCT04689828.
   Google Scholar
• Dellis A, Zagouri F, Liontos M, et al. Management of advanced prostate cancer: a systematic review of existing guidelines and recommendations. Cancer Treat Rev. 2019 Feb;73:54–61.
   Google Scholar
• Vitkin N, Nersesian S, Siemens DR, et al. The Tumor Immune Contexture of Prostate Cancer. Front Immunol. 2019;10:603.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020 Jan 14;52(1):17–35.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016 Mar 25;351(6280):1463–1469.
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994 Jun 3;264(5164):1415–1421.
   PubMed Web of Science ®Google Scholar
• Santoni M, Conti A, Piva F, et al. Role of STAT3 pathway in genitourinary tumors. Future Sci OA. 2015 Nov;1(3):Fso15.
   PubMed Web of Science ®Google Scholar
• Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007 Jun 28;251(2):199–210.
   PubMed Web of Science ®Google Scholar
• Bishop JL, Thaper D, Zoubeidi A. The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel). 2014 Apr 9;6(2):829–859.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhu Y, Lou W, et al. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate. 2014 Feb;74(2):201–209.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005 Oct 28;310(5748):644–648.
   PubMed Web of Science ®Google Scholar
• Yu J, Yu J, Mani RS, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010 May 18;17(5):443–454.
   PubMed Web of Science ®Google Scholar
• St John J, Powell K, Conley-Lacomb MK, et al. TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. J Cancer Sci Ther. 2012 Apr 26;4(4):94–101.
   PubMedGoogle Scholar